share_log

Merck & Co | 8-K: Merck Announces Third-Quarter 2024 Financial Results

Merck & Co | 8-K: Merck Announces Third-Quarter 2024 Financial Results

默沙東 | 8-K：默沙東公佈 2024 年第三季度財務業績
美股SEC公告 ·  10/31 18:46

牛牛AI助理已提取核心訊息

Merck & Co., Inc., a leading pharmaceutical company, reported its financial results for the third quarter of 2024 on October 31, 2024. The company announced total worldwide sales of $16.7 billion, marking a 4% increase from the third quarter of 2023, with growth excluding the impact of foreign exchange at 7%. KEYTRUDA, Merck's cancer drug, saw sales grow by 17% to $7.4 billion, while Animal Health sales increased by 6% to $1.5 billion. The company's GAAP EPS was $1.24, and Non-GAAP EPS was $1.57, both including a net charge of $0.79 per share related to business development transactions. Merck also highlighted significant milestones in its vaccine programs and the completion of the acquisition of CN201 (MK-1045) from Curon Biopharmaceutical. The company narrowed its expected worldwide sales range for the full year of 2024 to be between $63.6 billion and $64.1 billion and adjusted its Non-GAAP EPS outlook to be between $7.72 and $7.77, reflecting a net negative impact related to business development transactions.
Merck & Co., Inc., a leading pharmaceutical company, reported its financial results for the third quarter of 2024 on October 31, 2024. The company announced total worldwide sales of $16.7 billion, marking a 4% increase from the third quarter of 2023, with growth excluding the impact of foreign exchange at 7%. KEYTRUDA, Merck's cancer drug, saw sales grow by 17% to $7.4 billion, while Animal Health sales increased by 6% to $1.5 billion. The company's GAAP EPS was $1.24, and Non-GAAP EPS was $1.57, both including a net charge of $0.79 per share related to business development transactions. Merck also highlighted significant milestones in its vaccine programs and the completion of the acquisition of CN201 (MK-1045) from Curon Biopharmaceutical. The company narrowed its expected worldwide sales range for the full year of 2024 to be between $63.6 billion and $64.1 billion and adjusted its Non-GAAP EPS outlook to be between $7.72 and $7.77, reflecting a net negative impact related to business development transactions.
默沙東公司，一家領先的藥品公司，在2024年第三季度於2024年10月31日公佈了其財務業績。該公司宣佈全球總銷售額爲$167億，較2023年第三季度增長4%，不含匯率期貨影響的增長率爲7%。默沙東的抗癌藥-凱特魯達（KEYTRUDA）銷售額增長了17%，達到$74億，而動物保健品銷售額增長了6%，達到$15億。該公司的美國通用會計準則（GAAP）每股收益爲$1.24，非美國通用會計準則（Non-GAAP）每股收益爲$1.57，均包括每股$0.79的業務發展交易淨費用。默沙東還突出了其疫苗項目中的重要里程碑以及從康龍生物製藥處收購CN201（Mk-1045）的完成。該公司將2024年全年全球銷售額預期範圍調整爲$636億至$641億，並調整了非美國通用會計準則每股收益展望爲$7.72至$7.77，反映了與業務發展交易相關的淨負面影響。
默沙東公司，一家領先的藥品公司，在2024年第三季度於2024年10月31日公佈了其財務業績。該公司宣佈全球總銷售額爲$167億，較2023年第三季度增長4%，不含匯率期貨影響的增長率爲7%。默沙東的抗癌藥-凱特魯達（KEYTRUDA）銷售額增長了17%，達到$74億，而動物保健品銷售額增長了6%，達到$15億。該公司的美國通用會計準則（GAAP）每股收益爲$1.24，非美國通用會計準則（Non-GAAP）每股收益爲$1.57，均包括每股$0.79的業務發展交易淨費用。默沙東還突出了其疫苗項目中的重要里程碑以及從康龍生物製藥處收購CN201（Mk-1045）的完成。該公司將2024年全年全球銷售額預期範圍調整爲$636億至$641億，並調整了非美國通用會計準則每股收益展望爲$7.72至$7.77，反映了與業務發展交易相關的淨負面影響。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間